Search
SB-509
go.drugbank.com/drugs/DB05579InvestigationalSB-509 is under investigation in multiple clinical trials for the treatment of Diabetic Neuropathy.
Iproclozide
go.drugbank.com/drugs/DB09247ApprovedWithdrawnfatalities has resulted ultimately in the agent being discontinued. … Iproclozide is an irreversible and selective hydrazine class based monoamine oxidase inhibitor (MAOI).
LLL-3348
go.drugbank.com/drugs/DB05771ExperimentalThe botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.
TM5614
go.drugbank.com/drugs/DB16516InvestigationalAn animal study in mice fed a fast-food diet with TM5614 treatment showed improved metabolic measurements and reduced liver steatosis[L31673,L31678]. … Further investigation of this compound is underway, including an exploratry Phase II study for its efficacy and safety for high-risk hospitalized patients with severe COVID-19 pneumonia[L31688].
SOT-107
go.drugbank.com/drugs/DB05337InvestigationalSOT-107 is a drug that is a combination of a protein called transferrin and a poison called diphtheria toxin. This drug treat for a type of brain cancer called a high grade glioma brain tumour.
Adipiplon
go.drugbank.com/drugs/DB06579InvestigationalAdipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.
ALKS 29
go.drugbank.com/drugs/DB05723ExperimentalALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.
IDD-1
go.drugbank.com/drugs/DB05439ExperimentalEladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject. … As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.
Ostabolin-C
go.drugbank.com/drugs/DB05536InvestigationalOstabolin C was under investigation in clinical trial NCT00787358 (A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT
IDM-4
go.drugbank.com/drugs/DB05438ExperimentalIDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.